This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
BREDA, The Netherlands and GHENT,
April 24, 2013 /PRNewswire/ --
First program based on proprietary ABDEG™ technology to promote degradation and clearance of disease-causing autoantibodies
arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed its second product candidate this year into formal preclinical development.
Complementing its existing pipeline of four human mAb-based programs, arGEN-X has developed ARGX-113 as a human antibody Fc fragment. Exploiting its novel, proprietary technology called ABDEG™, ARGX-113 has been designed to clear and degrade circulating disease-causing autoantibodies. As arGEN-X' first ever ABDEG development program, ARGX-113 is an exciting and novel approach to treating potentially any IgG-mediated autoimmune disease. Such indications could include major autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, as well as a wide range of serious, orphan diseases for which there are currently insufficient treatment options, such as myasthenia gravis and immune thrombocytopenic purpura.
Development of ARGX-113 was based on preclinical studies originally conducted in the research group of Professor
Sally Ward at the
University of Texas Southwestern Medical Center, from which arGEN-X licensed the ABDEG technology in 2012. Data generated in Professor Ward's laboratory showed the ability of ABDEGs to markedly reduce inflammation in both preventative and established models of rheumatoid arthritis. Further preclinical studies of ARGX-113 are now being undertaken by arGEN-X, with an IND filing anticipated in 2015.
Tim Van Hauwermeiren, CEO of arGEN-X, said: "The therapeutic potential of ARGX-113 in multiple autoimmune diseases takes the progression of our pipeline to an exciting new level. In its broadest sense, we can envisage such a product potentially supplanting intravenous immunoglobulin (IVIG) in the treatment of autoimmunity. As well as the specific product potential of ARGX-113, we intend to outlicense our ABDEG technology to partners seeking to enhance therapeutic antibody potency in autoimmune disease. Furthermore, we see immediate applicability of ABDEGs in improving the efficacy of chronic disease treatment with biologics, including in the orphan drug space."